Aidoc receives CE mark for first commercial deep learning solution for radiologists
Leading healthcare AI company Aidoc have announced that it has received CE marking for the world’s first commercial head and neck deep learning medical imaging solution. This CE marking will allow for the widespread commercialisation of Aidoc’s solution across Europe.
Utilising deep learning to augment radiologists’ workflow and highlight anomalous cases, which are often highly urgent, the company’s solution comprehensively detects abnormalities in imaging of both the head and neck, an area responsible for a major portion of medical images.
Providing significant value for day-to-day diagnosis, time saved by Aidoc’s solution could be extremely impactful in trauma cases, where time can be the difference between the patient’s life and death.
This deep learning technology highlights a vast array of medical findings to help radiologists prioritise readings, aimed at facilitating interpretation and reducing time to decision when it matters most. Radiologists can now perform smart optimisation of their worklist by prioritising cases based on AI medical image analysis in conjunction with other clinically available data.
Based in Tel Aviv, Israel, Aidoc’s solution is agnostic to radiologists’ incumbent software, integrating seamlessly and providing immediate results, and has undergone a number of studies, both in the Europe and the US.
- EU Medical Device Regulations - The nightmare before Christmas
- Amazon shares could climb 20% if the company joined healthcare industry
- Microsoft Health: The healthcare revolutionaries
“The amount of medical imaging – especially CT and MR scans – is increasing dramatically, but the number of radiologists has plateaued, creating unsustainable bottlenecks and making the radiologist’s already complex work even more challenging,” explained Aidoc CEO Elad Walach.
“Our technology can have a monumental impact augmenting the radiology workflow, aimed at more cost-effective treatment for medical centers and practices, and the healthcare system as a whole. With the CE mark, we have a unique opportunity to update outdated technology for the benefit of hundreds of millions of Europeans.”
“In our clinical trial, Aidoc’s technology has demonstrated its ability to enhance our radiologists’ workflow, as abnormal scans can be prioritised and more carefully reviewed,” commented Dr. Barry D. Pressman, MD, Chairman of Imaging at Cedars-Sinai Medical Center, California.
“Our firsthand experience has led me to believe in the technology’s potential to achieve a significant increase in our radiologists’ productivity and accuracy. It’s a win both for our physicians and our patients. Aidoc’s AI powered solution will help our radiologists be their best, and streamline their workflow.”
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”